Core Insights - The company has reported a significant increase in cumulative orders for its core products, surpassing 230 units, with over 160 commercial orders for the TUMAI surgical robot, including nearly 120 new orders this year [1] - The TUMAI robot has achieved over 100 commercial installations globally, all of which have received signed acceptance reports from users, aligning with the company's revenue recognition policy [1] - TUMAI is the first domestic endoscopic surgical robot to reach 100 commercial installations, demonstrating its reliability and clinical stability, as well as advancements in quality compliance and production processes [1] Market Performance - In the domestic market, TUMAI has made significant progress in top public hospitals and high-end private hospitals, with 23% of installed hospitals being top-tier hospitals and over 90% being tertiary hospitals [2] - The company has established a high-quality installation pattern driven by clinical value and professional capability, enabling remote teaching, technical support, and collaborative surgeries across various hospital levels [2] - TUMAI's global market share is on the rise, with a rapidly developing ecosystem for robotic surgeries that integrates academic, technical, and clinical systems, covering over 40 countries and regions [2]